Viral hepatitis В after liver transplantation

Abstract

Chronic hepatitis B remains one of the most serious global health problems, being one of the main causes of cirrhotic transformation of the liver and hepatocellular carcinoma. The World health organization estimates that more than 350 million people in the world suffer from chronic hepatitis B, despite the vaccination, which significantly reduced the incidence. Since the active introduction of liver transplantation into clinical practice (mid-80s of the 20th century), the problem of infection of a transplanted liver with hepatitis B and C viruses, as well as the development of hepatocellular cancer against a background of viral infection before and after liver transplantation has not lost its relevance. About 5–10% of cases of liver transplants in adults are performed for liver cirrhosis and hepatocellular cancer in the outcome of chronic viral hepatitis B. The survival of liver recipients depends on many reasons, both surgical and not related to the surgical intervention itself. In this latter group of causes, the most frequent are infectious complications, rapidly progressing against the background of drug immunosuppression. Hepatitis B virus infection in liver transplant patients with liver cirrhosis caused by the hepatitis B virus (reactivation of hepatitis B virus infection) and de novo hepatitis B developed after transplantation in patients undergoing surgery is no exception. For liver diseases that are not associated with the hepatitis B virus. Timely diagnosis of various clinical forms of infection caused by the hepatitis B virus will help to avoid the development of manifest forms of this disease.

Keywords

hepatitis B virus / deoxyribonucleic acid hepatitis B virus / circular covalently closed deoxyribonucleic acid hepatitis B / core antigen of hepatitis B virus / antigen associated with the core of hepatitis B / chronic viral hepatitis B / latent infection caused by hepatitis B / virus reactivation of infection caused by virus hepatitis B / orthotopic liver transplantation, immunosuppressive therapy

References

[1] Андрейцева, О.И. Возможности ортотопической трансплантации печени при лечении больных с терминальными поражениями печени / О.И. Андрейцева // Consilium medicum. – 2004. – T 6. – C. 414–421.

[2] Габдрахманов, И.А. Клинико-вирусологическая и морфологическая характеристика хронического гепатита В на различных фазах заболевания: автореф. дис. ... канд. мед. Наук / И.А. Габдрахманов. – СПб.: ВМА, 2016. – 12 с.

[3] Готье, С.В. Трансплантация печени. Национальные клинические рекомендации / C.В. Готье [и др.] // Вестн. трансплантологии. – 2013. – T. 15, № 3. – C. 28–30.

[4] Готье, С.В. Донорство и трансплантация органов в Российской Федерации в 2016 году. IX сообщение регистра Российского трансплантологического общества / С.В. Готье [и др.] // Вестн. трансплантологии и искусственных органов. – 2017. – Т 19, № 2. – С. 6–26.

[5] Готье, С.В. Национальные клинические рекомендации: посмертное донорство органов / С.В. Готье [и др.] // Вестн. трансплантологии и искусственных органов. – 2013. – Т 13, № 2. – С. 7–28.

[6] Михалов, М.И. Проект программы по контролю и ликвидации вирусных гепатитов как проблемы общественного здоровья в Российской Федерации / М.И. Михайлов [и др.] // Инфекционные болезни: новости, мнения, обучение. – 2018. – Т. 7, № 2. – С. 52–58.

[7] Пат. № 2633755 Российская Федерация. Способ выявления в биологическом материале ДНК вируса гепатита В при низкой вирусной нагрузке на основе двухэтапной ПЦР / Ю.В. Останкова, А.В. Семенов, А.А. Тотолян; опубл. 17.10.2017, бюлл. № 29. – С. 27–31.

[8] Хубития, М.Ш. История отечественной трансплантологии, приоритеты и особенности развития / М.Ш. Хубития // Трансплантология. – 2011. – Т. 1. – С. 55–64.

[9] Эсауленко, Е.В. Клинико-лабораторная характеристика оккультного гепатита В / Э.В. Эсауленко [и др.] // Журн. инфектол. – 2016. – Т. 8, № 1. – С. 66–72.

[10] Angelico, M. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the Liver Match cohort study / M. Angelico [et al.] // Journal of hepatology. – 2013. – Vol. 58, № 4. – P. 715–723.

[11] Calne, R.Y. Liver transplantation in man – II, A report of two orthotopic liver transplants in adult recipients / R.Y. Calne [et al.] // British Medical Journal. – 1968. – Vol. 4. – P. 541–546.

[12] Castells, L. Сlinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation / L. Castells [et al.] // Liver Transplantation. – 2002. – Vol. 8, № 10. – P. 892–900.

[13] Cholongitas, E. Liver grafts from anti-hepatitis B core positive donors: a systematic review / E. Cholongitas, G.V. Papatheodoridis, A.K. Burroughs // Journal of hepatology. – 2010. – Vol. 52, № 2, – P. 272–279.

[14] Dickson, R. C. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen / R.C. Dikson [et al.] // Gastroenterology. – 1997. – Vol.

[15] 113, № 5. – P. 1668–1674.

[16] European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection // Journal of hepatology. – 2017. – Vol. 67, № 2. – P. 370–398.

[17] El-Sarag, H.B. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma / H.B El-Sarag // Gastroenterology. – 2012. – Vol. 142, № 6. – P. 1264–1273.

[18] International data on organ donation and transplantation activity, waiting list and family refusals. Year 2010 // Newsletter transplantant. – 2011. – P. 31–46.

[19] Joya-Vazquez, P.P. Impact of anti-hepatitis B-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis / P.P. Joya-Vazquez [et al.] // Transplantation. – 2002. – Vol. 73, № 10. – P. 1598–1602.

[20] Lok, A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched / A. Lok // Hepatology communications. – 2019. – Vol. 3, № 1. – P. 8–19.

[21] Nevin, Y. Prophylaxis Against Recurrance of Hepatitis B Virus After Liver Transplantation: A Retrospective Analysis Spanning 20 Years / Y. Nevin [et al.] // Journal. Liver International. – 2008. – Vol. 28, № 1. – Р. 72–78.

[22] Papastergiou, V. Global Epidemiology of Hepatitis B Virus (HBV) Infection / V. Papastergiou // Current Hepatology Reports. – 2015. – Vol. 14, № 3. – P. 171–178.

[23] Rambusch, E.G. De novo hepatitis B infection after liver transplantation – evidence for the need of active hepatitis В vaccination of liver transplantation candidates / E.G. Rambusch [et al.] // Z. Gastroenterolоgy. – 1998. – Vol. 36, № 12. – P. 1027–1035.

[24] Starzl, T.E. Homotransplantation of the liver / T.E. Starzl [et al.] // Transplantation. – 1967. – Vol. 5. – P. 790–803.

[25] Suzuki, F.H. Correlation between serum hepatitis B virus core- related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients / F.H. Suzuki [et al.] // Journal of medical virology. – 2009. – Vol. 81, № 1. – P. 27–33.

[26] Wong, D.K. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection / D. K. Wong [et al.] // Journal of Clinical Microbiology. – 2007. – Vol. 45, № 12. – P. 3942–3947.

RIGHTS & PERMISSIONS

Eco-Vector